Prognostic significance of CD4+ and CD8+ T cell infiltration within cancer cell nests in vulvar squamous cell carcinoma

International Journal of Gynecological Cancer

Volumn 21, Issue 4, 2011, Pages 717-721

  Sznurkowski, Jacek Jan ^a   Zawrocki, Anton ^a   Emerich, Janusz ^a   Biernat, Wojciech ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

CD4; CD8; Prognosis; TILs; Vulvar SCC

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CELL; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNITY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; VULVA CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOPLASTIC STEM CELLS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; STEM CELL NICHE; SURVIVAL ANALYSIS; VULVAR NEOPLASMS;

EID: 80051873957     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182131f36     Document Type: Article

References (25)

1. Sturgeon SR, Bronton LA, Devesa SS, et al. In situ and invasive vulvar cancer incidence trends (1973 to 1987). Am J Obstet Gynecol. 1992;166:1482-1485.
2. Ansink AC, Heintz AP. Epidemiology and etiology of squamous cell carcinoma of the vulva. Eur J Obstet Gynecol Reprod Biol. 1993;48:111-115. (Pubitemid 23108941)
3. Coulter J, Gleeson N. Local and regional recurrence of vulval cancer: management dilemmas. Best Pract Res Clin Obstet Gynaecol. 2003;17:663-681. (Pubitemid 37168286)
4. Monaghan JM. The management of carcinoma of the vulva. In: Shepherd JH, Monaghan JM, eds. Clinical Gynaecological Oncology. 2nd ed. Oxford, UK: Blackwell Scientific Publications; 1990:140-167.
5. Beller U, Quinn MA, Benedet JL, et al. Carcinoma of the vulva. In J Gynaecol Obstet. 2006;95:S7-S27.
6. Maggino T, Landoni F, Sartori E, et al. Patterns of recurrence in patients with squamous cell carcinoma of the vulva. A multicenter CTF Study. Cancer. 2000;89:116-122. (Pubitemid 30451281)
7. Gadducci A, Cionini L, Romanini A, et al. Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol. 2006;60:227-241. (Pubitemid 44709620)
8. Rosenberg SA. The immunotherapy of solid cancers based on cloning the genes encoding tumor rejection antigenes. Annu Rev Med. 1996;47:481-491. (Pubitemid 26138906)
9. Mukai S, Kjaergaard J, Shu S, et al. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res. 1999;59:5245-5249. (Pubitemid 29503989)
10. Willimsky G, Blankenstein T. Iterleukin-7/B7.1-encoding adenoviruses induce rejection of transplanted but not nontransplanted tumors. Cancer Res. 2000;60:685-692. (Pubitemid 30094568)
11. Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998;58:3491-3494. (Pubitemid 28376536)
12. Schumacher K, Haensch W, Roefzaad C, et al. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. 2001;61:3932-3936. (Pubitemid 32720953)
13. Oudejans JJ, Jiwa NM, Kummer JA, et al. Activated cytotoxic T cells as a prognostic marker in Hodgkin's disease. Blood. 1997;89:1376-1382. (Pubitemid 27080002)
14. Berge RL, Dukers DF, Oudejans JJ, et al. Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma. Blood. 1999;93:2688-2696. (Pubitemid 29181202)
15. Toes RE, Ossendorp F, Offringa R, et al. CD4 T cells and their role in antitumor immune responses. J Exp Med. 1999;189: 753-756. (Pubitemid 29189679)
16. Cohen PA, Peng L, Plautz GE, et al. CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit Rev Immunol. 2000;20:17-56. (Pubitemid 30191901)
17. Pardoll DM, Topalian SL. The role of CD4+ T cells responses in antitumor immunity. Curr Opin Immunol. 1998;10:588-594. (Pubitemid 28479193)
18. Ping Y, Yang-Xin F. Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest. 2006;86:231-245.
19. Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. 2001;22:269-276.
20. Shepherd JH. Cervical and vulva cancer: changes in FIGO definitions of staging. Br J Obstet Gynaecol. 1996;103:405-406. (Pubitemid 26141629)
21. Pecorelli S. FIGO Committee on Gynecologic Oncology. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105:103-104.
22. Nakano O, Sato M, Naito Y, et al. Proliferative activity of intratumoral CD8+ T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 2001;61:5132-5136. (Pubitemid 32681545)
23. Yoshida N, Abe H, Ohkuri O, et al. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol. 2006;28:1089-1098.
24. Wakabayashi O, Yamazaki K, Oizumi S, et al. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell cancers. Cancer Sci. 2003;94:1003-1009. (Pubitemid 37521216)
25. Vicary AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev. 2002;13:143-154. (Pubitemid 34229389)